IB2 抗体 (AA 31-130) (Cy7)
Quick Overview for IB2 抗体 (AA 31-130) (Cy7) (ABIN1708280)
抗原
See all IB2 (JIP-2) 抗体适用
宿主
克隆类型
标记
应用范围
- 
    - 
                                            抗原表位
- AA 31-130
- 
                                            预测反应
- Human,Mouse,Rat,Cow,Horse
- 
                                            纯化方法
- Purified by Protein A.
- 
                                            免疫原
- KLH conjugated synthetic peptide derived from human JIP2
- 
                                            亚型
- IgG
 
- 
                                            
- 
    
- 
    - 
                                            应用备注
- 
                        IF(IHC-P) 1:50-200
 IF(IHC-F) 1:50-200
 IF(ICC) 1:50-200
- 
                                            限制
- 仅限研究用
 
- 
                                            
- 
    - 
                                            状态
- Liquid
- 
                                            浓度
- 1 μg/μL
- 
                                            缓冲液
- Aqueous buffered solution containing 0.01M TBS ( pH 7.4) with 1 % BSA, 0.03 % Proclin300 and 50 % Glycerol.
- 
                                            储存液
- ProClin
- 
                                            注意事项
- This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE, which should be handled by trained staff only.
- 
                                            储存条件
- -20 °C
- 
                                            储存方法
- Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles.
- 
                                            有效期
- 12 months
 
- 
                                            
- 
    - IB2 (JIP-2) (C-Jun-Amino-Terminal Kinase-Interacting Protein 2 (JIP-2))
- 
                                            别名
- JIP2
- 
                                            背景
- 
                        Synonyms: MAPK8IP2, C jun amino terminal kinase interacting protein 2, C-jun-amino-terminal kinase-interacting protein 2, Homologous to mouse JIP 1, IB 2, IB-2, IB2, Islet brain 2, Islet-brain-2, JIP 2, JIP-2, JIP2, JIP2_HUMAN, JNK interacting protein 2, JNK MAP kinase scaffold protein 2, JNK MAP kinase scaffold protein JIP2, JNK-interacting protein 2, MAPK8IP2, Mitogen activated protein kinase 8 interacting protein 2, Mitogen-activated protein kinase 8-interacting protein 2, PRKM8 interacting protein like, PRKM8IPL. Background: c-Jun NH2-terminal kinases (JNKs) are distant members of the MAP kinase family (1). JNK1 is activated by dual phosphorylation at a Thr-Pro-Tyr motif in response to ultraviolet (UV) light, and it functions to phosphorylate c-Jun at amino terminal serine regulatory sites, Ser-63 and Ser-73, resulting in transcriptional activation (2-5). Two additional JNK family members have been identified as JNK2 and JNK3 (3). JIP-1 (for JNK interacting protein-1) has been identified as a cytoplasmic inhibitor of JNK that retains JNK in the cytoplasm, thereby inhibiting JNK-regulated gene expression. Evidence suggests that JNK1 and JNK2 bind to JIP-1 with greater affinity than to ATF-2 and c-Jun, which are targets of the JNK signaling pathway. JIP-1 contains an amino terminal JNK binding domain and a carboxy terminal SH3 domain. ATF-2 and c-Jun also contain the JNK binding domain and are thought to compete with JIP-1 for JNK binding (6). Multiple splice variants if JIP-1, including JIP-1b, JIP-1c (also designated islet-brain 1 or IB-1), JIP-2a, JIP-2b and JIP-3, have been identified in brain (7). 
 抗原
- 
                    
 
                                     
                                     
                                    